Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market 2027 by Therapy, Route of Administration, Distribution Channel, and Geography | The Insight Partners

Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecast to 2027 - Covid-19 Impact and Global Analysis By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy); Route of Administration (Injectable, Oral); Distribution Channel (Hospital and Retail Pharmacies, Online Distribution), and Geography

Report Code: TIPRE00016400 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Castration-resistant prostate cancer (CRPC) is a type of cancer that occurs in men who have undergone androgen deprivation therapy (ADT) and is regardless of castrate levels of testosterone. The cancer is seen among many older men as there is a rapidly rising PSA level resulting in metastatic CRPC.

MARKET DYNAMICS

The castration-resistant prostate cancer (CRPC) therapeutics market growth is expected to grow due to growing geriatric population, rising incidences of prostate disorders and cancers, and growing demand for biopharmaceutical based products for prostate cancer. The development and investment of precision medicines for prostate cancer treatment is expected to serve growth opportunities for the market growth.

MARKET SCOPE

The "Castration-resistant Prostate Cancer (CRPC) Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of castration-resistant prostate cancer (CRPC) therapeutics market with detailed market segmentation by therapy, route of administration, and distribution channel. The castration-resistant prostate cancer (CRPC) therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in castration-resistant prostate cancer (CRPC) therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The castration-resistant prostate cancer (CRPC) therapeutics market is segmented on the basis of, therapy, route of administration, and distribution channel. Based on therapy, the market is divided into chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. Based on route of administration the market is classified as injectable, and oral. And based on distribution channel, the market is classified as hospital and retail pharmacies, and online distribution.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the castration-resistant prostate cancer (CRPC) therapeutics market based on various segments. It also provides market size and forecast estimates from year 2019 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The castration-resistant prostate cancer (CRPC) therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting castration-resistant prostate cancer (CRPC) therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the castration-resistant prostate cancer (CRPC) therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS

The report covers key developments in the castration-resistant prostate cancer (CRPC) therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from castration-resistant prostate cancer (CRPC) therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for castration-resistant prostate cancer (CRPC) therapeutics in the global market. Below mentioned is the list of few companies engaged in the castration-resistant prostate cancer (CRPC) therapeutics market.

The report also includes the profiles of key players in castration-resistant prostate cancer (CRPC) therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

- Bayer AG
- AbbVie Inc.
- Johnson and Johnson
- Sanofi
- Amgen Inc.
- Novartis AG
- OncoGenex Technologies Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Astellas Pharma Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.



Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market - By Therapy
1.3.2 Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market - By Route of Administration
1.3.3 Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market - By Distribution Channel
1.3.4 Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY
7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. CHEMOTHERAPY
7.3.1. Overview
7.3.2. Chemotherapy Market Forecast and Analysis
7.4. HORMONAL THERAPY
7.4.1. Overview
7.4.2. Hormonal Therapy Market Forecast and Analysis
7.5. IMMUNOTHERAPY
7.5.1. Overview
7.5.2. Immunotherapy Market Forecast and Analysis
7.6. RADIOTHERAPY
7.6.1. Overview
7.6.2. Radiotherapy Market Forecast and Analysis
8. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. INJECTABLE
8.3.1. Overview
8.3.2. Injectable Market Forecast and Analysis
8.4. ORAL
8.4.1. Overview
8.4.2. Oral Market Forecast and Analysis
9. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL AND RETAIL PHARMACIES
9.3.1. Overview
9.3.2. Hospital and Retail Pharmacies Market Forecast and Analysis
9.4. ONLINE DISTRIBUTION
9.4.1. Overview
9.4.2. Online Distribution Market Forecast and Analysis
10. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Overview
10.1.2 North America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis
10.1.3 North America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Therapy
10.1.4 North America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.1.6.1.1 United States Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.1.6.1.2 United States Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.1.6.1.3 United States Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.1.6.2 Canada Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.1.6.2.1 Canada Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.1.6.2.2 Canada Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.1.6.2.3 Canada Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.1.6.3 Mexico Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.1.6.3.1 Mexico Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.1.6.3.2 Mexico Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.1.6.3.3 Mexico Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Overview
10.2.2 Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis
10.2.3 Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Therapy
10.2.4 Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.2.6.1.1 Germany Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.2.6.1.2 Germany Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.2.6.1.3 Germany Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.2.6.2 France Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.2.6.2.1 France Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.2.6.2.2 France Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.2.6.2.3 France Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.2.6.3 Italy Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.2.6.3.1 Italy Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.2.6.3.2 Italy Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.2.6.3.3 Italy Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.2.6.4 Spain Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.2.6.4.1 Spain Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.2.6.4.2 Spain Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.2.6.4.3 Spain Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.2.6.5 United Kingdom Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.2.6.5.1 United Kingdom Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.2.6.5.2 United Kingdom Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.2.6.5.3 United Kingdom Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.2.6.6 Rest of Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.2.6.6.1 Rest of Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.2.6.6.2 Rest of Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.2.6.6.3 Rest of Europe Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Overview
10.3.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Therapy
10.3.4 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.3.6.1.1 Australia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.3.6.1.2 Australia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.3.6.1.3 Australia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.3.6.2 China Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.3.6.2.1 China Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.3.6.2.2 China Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.3.6.2.3 China Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.3.6.3 India Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.3.6.3.1 India Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.3.6.3.2 India Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.3.6.3.3 India Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.3.6.4 Japan Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.3.6.4.1 Japan Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.3.6.4.2 Japan Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.3.6.4.3 Japan Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.3.6.5 South Korea Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.3.6.5.1 South Korea Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.3.6.5.2 South Korea Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.3.6.5.3 South Korea Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.3.6.6.2 Rest of Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.3.6.6.3 Rest of Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Overview
10.4.2 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Therapy
10.4.4 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.4.6.1.1 South Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.4.6.1.2 South Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.4.6.1.3 South Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.4.6.2 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.4.6.2.1 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.4.6.2.2 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.4.6.2.3 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.4.6.3 U.A.E Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.4.6.3.1 U.A.E Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.4.6.3.2 U.A.E Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.4.6.3.3 U.A.E Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.4.6.4.2 Rest of Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Overview
10.5.2 South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Therapy
10.5.4 South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.5.6.1.1 Brazil Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.5.6.1.2 Brazil Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.5.6.1.3 Brazil Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.5.6.2 Argentina Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.5.6.2.1 Argentina Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.5.6.2.2 Argentina Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.5.6.2.3 Argentina Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
10.5.6.3 Rest of South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market
10.5.6.3.1 Rest of South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Therapy
10.5.6.3.2 Rest of South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Castration-Resistant Prostate Cancer (CRPC) Therapeutics Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CASTRATION-RESISTANT PROSTATE CANCER (CRPC) THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. BAYER AG
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. ABBVIE INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. JOHNSON AND JOHNSON
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. SANOFI
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. AMGEN INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. NOVARTIS AG
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. ONCOGENEX TECHNOLOGIES INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PFIZER INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. GLAXOSMITHKLINE PLC
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. ASTELLAS PHARMA INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Bayer AG
2. AbbVie Inc.
3. Johnson and Johnson
4. Sanofi
5. Amgen Inc.
6. Novartis AG
7. OncoGenex Technologies Inc.
8. Pfizer Inc.
9. GlaxoSmithKline plc
10. Astellas Pharma Inc.
TIPRE00016400
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking